The firm expects to begin the Phase I trial in HER2-positive breast and gastric cancers in the first half of 2026.
The company plans to launch a Phase I trial of its lead autologous cell therapy for renal cell carcinoma in 2026.
The nonprofit subsidiary Orphan Therapies will be the exclusive commercializaiton partner for the Wiskott-Aldrich syndrome gene therapy in the US.
Experts at SABCS said better prospective trials of ctDNA and more sensitive assays could bring ctDNA testing closer to the ...
The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback